In a move to further increase manufacturing capacity for its active pharmaceutical ingredients (API) used to treat chronic diseases, Eli Lilly has announced a $5.3 billion boost to its Lebanon, Indiana, facility investment. This brings a total of $9 billion invested in the state and marks the largest investment toward API manufacturing in the country. “This multi-site campus will make our latest medicines, including Zepbound and Mounjaro, support pipeline growth and leverage the latest technology and automation for maximum efficiency, safety and quality control,” says Eli Lilly CEO David A. Ricks. “Importantly, we are investing in our home state of Indiana, creating high-wage, advanced manufacturing, engineering and science jobs for hundreds of current and future Hoosier families.” The company anticipates the new site, located in the LEAP Research and Innovation District, will aid in meeting the demand for treatments in both diabetes and obesity. Once construction is complete about 900 new direct jobs will be created.
|